10 Best Clean Energy Stocks To Watch Right Now

10 Best Clean Energy Stocks To Watch Right Now: Neogenomics Inc (NEO)

NeoGenomics, Inc. (NeoGenomics) operates a network of cancer-focused testing laboratories. The Company offers testing services, including Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing, this is the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens, and molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level.

The cancer testing services, that the Compan y offers to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. In areas where the Company does not provide services to community-based pathology practices, it may directly serve oncology, dermatology, urology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic and molecular testing services. NeoGenomics services these types of clients with a global service offering where it performs both the technical and professional components of the tests ordered.

The Company offers tech-only flow cytometry and immunohistochemistry testing services. These types of testing services generally allow the professional interpretation component of a test to be billed separately from the technical compon! ent. Its NeoFISH, NeoFLOW and other tech-only service offerings allow properly trained and credentialed community-bas ed pathologists to extend their own practices by performing ! professional interpretations services.

The Company's tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order global services and receive a test report, which includes a NeoGenomics Pathologist's interpretation of the test results.

The Company also offers a set of global services to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who are looking for specialists to interpret the testing results for them. In its global service offerings, its lab performs the technical component of the tests and its doctor of medicine (M.D.s) and doctor of philosophy (Ph.D) s to provide the interpretation services. Its genetic pathology solutions (GPS) report summarizes all relevant case data from its global servic es on one summary report.

The Company competes with General Electric Healthcare Services and Novartis, A.G.

Advisors' Opinion:

• [By John Udovich]

  One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus or esophageal cancer (the former often leads to the latter) – a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus,  a condition that develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the normal esophageal lining is replaced with abnormal cells (known as Barrett's tissue), putting patients at greater risk of developing! cancer o! f the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective. This means that early detection is important along with r egular surveillance is recommended. 

source from Top Stocks For 2015:http://www.topstocksblog.com/10-best-clean-energy-stocks-to-watch-right-now-2.html